Updated At Apr 18, 2026
Partner Labs, Pharmacies, and Insurers: Sharing Health Data Safely
A practical, India-focused guide for healthcare leaders to build a consent-led, DPDP- and ABDM-aligned data-sharing model with labs, pharmacies, and insurers.
Key takeaways
- Treat consent as a supply chain that must flow across hospitals, labs, pharmacies, and insurers, not just a checkbox at registration.
- Map real-world data flows and risk hotspots before selecting tools or signing new partner contracts.
- Align DPDP and ABDM responsibilities with clear roles, minimum technical controls, and evidence-ready audit trails.
- Use a phased 12–18 month roadmap to modernise data sharing without disrupting clinical workflows or claims operations.
- Evaluate consent platforms on regulatory alignment, integration fit, language support, reliability, and governance features instead of just UI or price.
The new reality of partner data sharing in Indian healthcare
Mapping data flows between providers, labs, pharmacies, and insurers
| Journey stage | Key data shared | Typical partners involved | Risk hotspots to check |
|---|---|---|---|
| Registration & appointment | Demographics, ABHA (where used), contact details, insurance ID, basic medical history. | Appointment aggregators, call centres, TPAs, front-office vendors. | Over-collection, bundled consent for multiple future uses, unclear consent for onward sharing to partners. |
| Diagnostics (lab/radiology) | Test orders, clinical notes, reports, images, identifiers, billing information. | External labs, radiology centres, LIS/RIS vendors, sample collection partners. | Reports shared over email or messaging apps, shared workstations, weak access control and logging at partner sites. |
| Pharmacy & medication fulfilment | E-prescriptions, diagnosis codes, chronic conditions, dosage and refill details. | In-house pharmacies, third-party pharmacy chains, e-pharmacy platforms, drug delivery partners. | Use of prescription data for cross-selling or marketing, data sharing with analytics or ad-tech vendors without explicit consent. |
| Claims & pre-authorisation | Detailed clinical summaries, investigation reports, procedure notes, cost estimates, KYC and payment data. | Insurers, TPAs, empanelment partners, external claims-processing platforms. | Over-sharing of clinical details, unclear retention and deletion timelines, use of data for underwriting or profiling beyond disclosed purposes. |
| Post-visit engagement & analytics | Visit history, adherence data, device or app data, feedback scores, communication logs. | CRM vendors, digital marketing partners, wellness platforms, analytics providers. | Secondary use of health data beyond original consent, weak de-identification, lack of opt-out mechanisms for patients. |
Regulatory and trust framework for sharing health data safely
At a high level, decision-makers should be clear on a few core concepts:
- Digital Personal Data Protection Act, 2023 (DPDP): establishes roles such as data principal (patient), data fiduciary (organisation deciding purposes and means of processing), data processor (processing on behalf), and consent manager, and sets obligations and penalties for processing digital personal data.[1]
- Ayushman Bharat Digital Mission (ABDM): aims to enable secure, interoperable exchange of personal health records using building blocks such as ABHA numbers and national registries for providers and facilities, with sharing based on informed consent.[2]
- ABDM building blocks: describe Health Information Providers (HIPs), Health Information Users (HIUs), and the Health Information Exchange & Consent Manager (HIE-CM), through which consented health data sharing between entities is orchestrated.[3]
- DPDP obligations in healthcare: emerging rules and sectoral guidance emphasise reasonable security safeguards, breach notification, purpose limitation, data minimisation, and heightened care for children’s data and other sensitive categories.[5]
- Ethical context: expert analyses indicate that while DPDP and ABDM are important advances, gaps remain in how patient privacy and informed consent are operationalised in everyday healthcare practice, so organisations need to go beyond bare legal compliance.[4]
Designing a safe data-sharing operating model with your partners
Use this checklist to convert legal and architectural principles into a concrete operating model with labs, pharmacies, insurers, and technology vendors.
-
Map your consent supply chainDocument every point where patient data leaves your core systems—what is shared, with whom, for what purpose, and how consent is captured or referenced today.
- Include partner labs, pharmacies, insurers/TPAs, and all HIS/LIS/EMR, CRM, and claims vendors.
- Highlight high-risk journeys such as high-value surgeries, chronic-disease programs, and cashless claims.
-
Define your policy and data minimisation baselineSet explicit rules for what minimum data each partner type should receive for a given purpose, and for how long they may retain it before deletion or anonymisation.
- Map each purpose to a lawful basis under DPDP and, where relevant, to ABDM roles such as HIP/HIU.
- Prohibit partners from using shared health data for unrelated analytics, ads, or cross-selling without fresh, explicit consent.
-
Allocate responsibilities and update contractsClarify which party is the data fiduciary and which parties act as data processors for each flow, then align contracts and operating procedures accordingly.
- Include minimum security standards, breach-notification timelines, and cooperation duties for responding to patient rights requests.
- Specify rights to audit or obtain evidence of safeguards and consent logs from partners and sub-processors.
-
Set minimum technical controls for all partnersAgree on a baseline of technical safeguards such as encryption in transit and at rest, role-based access control, strong authentication, secure APIs, and tamper-evident logs.
- Discourage routine sharing of clinical data over email or consumer messaging apps; prefer API or secure portal-based exchange.
- Align logging formats and identifiers (e.g., consent IDs, ABHA IDs where applicable) to make investigations and audits faster.
-
Embed consent and logging into workflowsEnsure that consent capture, verification, and revocation are integrated into clinical and operational workflows instead of relying on manual spreadsheets or ad hoc approvals.
- Use unique consent IDs that can be referenced across your HIS/LIS/EMR, lab systems, pharmacy platforms, and insurer systems.
- Maintain system-generated audit trails for access and sharing events, capturing who accessed what data, for which purpose, and under which consent.
-
Govern, train, and iterateCreate a cross-functional governance forum spanning clinical, operations, IT, legal, and partner management to oversee partner data sharing and review metrics regularly.
- Train internal teams and key partner staff on new consent flows, escalation paths, and breach-response playbooks.
- Review incidents, near-misses, and audit findings quarterly to refine policies, controls, and partner selection criteria.
| Partner type | Example data received | Minimum safeguards to require | Contract and governance focus |
|---|---|---|---|
| Diagnostic lab partner | Orders, identifiers, clinical notes, reports, billing and payment references. | Secure interfaces or portals, strong authentication, role-based access, encrypted storage, retention limits, tamper-evident logging of report access and downloads. | Clear processor role, restrictions on secondary use, obligation to notify and cooperate in incidents, right to audit or seek third-party certifications where appropriate. |
| Pharmacy partner (in-house or external) | E-prescriptions, diagnosis or indication codes, patient identifiers, dispensing and refill history, payment data. | Controlled access to prescription data, use limitation for fulfilment and safety, clear opt-in for any marketing, strong device and network security at retail outlets. | Explicit prohibitions on data resale or sharing with ad-tech partners, rules for loyalty programmes, and clear deletion or anonymisation timelines after fulfilment. |
| Insurer / TPA / claims platform | Pre-authorisation packets, discharge summaries, investigation reports, cost estimates, KYC, bank details, communication logs. | Strong network segmentation, encryption, access reviews, data loss prevention controls, and structured logging for every access or download of medical records. | Scope of use (claims servicing vs underwriting vs analytics), restrictions on profiling, data-sharing with reinsurers, and joint responsibilities for responding to patient rights requests and regulators. |
| Health-tech vendors (HIS/LIS/EMR, CRM, consent tools, analytics) | All categories of patient data depending on modules used, including identifiers, clinical, financial, and communication data. | Secure development practices, environment segregation, strong encryption, access control, monitoring, and tested incident-response procedures; clear environment for production vs test data. | Data processing addendums, sub-processor controls, cross-border transfer clauses where applicable, and regular security and compliance reporting to your governance forum. |
Troubleshooting common partner-data issues
As you tighten partner data sharing, you will encounter friction. These patterns and responses can help:
- Partner resists new consent or logging requirements: surface the business rationale—reputational risk, regulatory expectations, and patient trust—and start with a limited pilot that demonstrates benefits with minimal operational burden.
- Legacy systems cannot store consent IDs or logs: consider a lightweight middleware or consent platform that stores consent centrally and exposes IDs and status via APIs, while you phase modernisation of older HIS/LIS modules.
- Clinicians or staff bypass digital flows (e.g., sharing reports over messaging apps): investigate root causes such as poor UX or latency, fix them quickly, and reinforce policies with training and monitoring rather than only punitive action.
- Unclear responsibility after an incident: pre-define a RACI for breaches and near-misses, including who leads patient communication, forensic analysis, and regulator engagement, and embed it in contracts and runbooks before an event occurs.
Implementation roadmap, KPIs, and evaluating consent platforms
A realistic 12–18 month roadmap for a mid-sized provider or health-tech platform can be phased to reduce disruption while building strong foundations.
-
0–3 months: discover and prioritiseMap current data flows, partner list, and existing consent practices across key journeys such as OPD, IPD, diagnostics, and claims.
- Form a steering group with an executive sponsor from the C-suite and representation from clinical, IT, legal, and operations.
- Identify obvious high-risk gaps, such as lack of traceable consent for data sent to certain labs or TPAs, and define immediate guardrails.
-
3–6 months: design and choose toolingDefine your target consent supply chain, policy baseline, and technical standards; then decide which capabilities to build and which to buy.
- Shortlist consent and integration platforms that can model DPDP consent requirements, support ABDM flows where relevant, and integrate with your HIS/LIS/EMR stack.
- Run a proof-of-concept on a narrow but meaningful journey, such as partner lab integrations for day-care procedures or a high-volume TPA.
-
6–12 months: implement high-risk journeysRoll out the operating model and supporting technology for prioritised journeys, refining based on clinician, partner, and patient feedback.
- Integrate HIS/LIS/EMR, lab systems, pharmacy systems, and claims platforms with your consent and audit-trail layer in a phased manner.
- Update partner contracts, run joint drills for breach scenarios, and onboard partner staff to new access and consent-verification processes.
-
12–18 months: scale and institutionaliseExtend coverage to additional sites and partners, embed KPIs into management reviews, and prepare artefacts you would rely on during an external audit or inquiry.
- Conduct internal and third-party audits of consent logs, access logs, and partner controls; track closure of findings in your governance forum.
- Refresh partner due diligence, including security questionnaires and references, at agreed intervals or after material incidents.
- Share of partner data transactions linked to a verifiable consent record or consent ID, by journey and partner category.
- Average time to respond to patient data access, correction, or deletion requests that involve partner-held data.
- Number and severity of consent- or privacy-related complaints received from patients and partners each quarter.
- Number of audit findings related to partner data sharing and the median time taken to close them.
- Unplanned downtime in consent and audit-trail services that materially affects care delivery or claims processing.
How to evaluate consent management and integration platforms
Use these lenses when comparing options:
- Regulatory alignment and auditability: ability to model consent requirements under the DPDP framework, capture granular purposes and notices, maintain system-generated audit trails, and produce regulator-ready reports when needed.[1]
- Security and availability: encryption-led architecture, strong access control, segregation of duties, tested incident-response flows, clear SLAs, and high uptime commitments aligned to clinical and claims-critical operations.
- Integration and scalability: API-first design, SDKs for web and mobile apps, connectors for HIS/LIS/EMR and claims platforms, and the ability to propagate consent IDs across multiple partners without brittle point-to-point integrations.
- User experience and language coverage: intuitive experiences for patients, front-line staff, and compliance teams, with support for relevant Indian languages and low-friction consent journeys.
- Governance and reporting: role-based dashboards for legal, compliance, and operations leaders; configurable alerts; and analytics that highlight high-risk partners, journeys, or locations.
Common mistakes to avoid when sharing data with partners
- Treating consent as a one-time checkbox at registration instead of journey- and purpose-specific permissions that travel with the data to labs, pharmacies, and insurers.
- Allowing partners to reuse patient data for unrelated analytics, marketing, or cross-selling without obtaining separate, explicit consent and documenting that legal basis.
- Relying on email, spreadsheets, or consumer messaging apps as primary channels for exchanging clinical data with partners, making security, traceability, and deletion extremely hard.
- Leaving pharmacies, TPAs, and smaller diagnostics providers outside your formal governance, training, and audit scope while focusing only on large hospital or insurer relationships.
- Delaying investment in structured audit trails, logs, and dashboards until after a breach or regulator query, when it is too late to backfill reliable evidence.
Common questions from healthcare leaders
FAQs
Not always, but often. Under India’s digital personal data protection framework, the entity that decides the purposes and means of processing digital personal data is the data fiduciary; partners that process data on its behalf are data processors.[1]
In many care journeys you will be the primary data fiduciary, and labs, pharmacies, or TPAs will act as processors for specific flows. However, some partners may be separate fiduciaries for their own purposes. Map each data flow and role with legal counsel rather than assuming a single pattern.
Consent should be free, specific, informed, unambiguous, and limited to clearly stated purposes, with an easy way for the patient to withdraw it and know the consequences of doing so.[1]
In multi-party journeys, capture consent in a structured way that references specific partners or categories (e.g., external labs, empanelled insurers), attaches a consent ID, and propagates that ID and purpose to every system that will access the data. Avoid bundled language that hides multiple uses inside one checkbox.
ABDM’s architecture is built around entities such as Health Information Providers (HIPs), Health Information Users (HIUs), and the Health Information Exchange & Consent Manager (HIE-CM), with consented data exchange often linked to a patient’s ABHA number.[3]
When you participate in ABDM flows, treat them as one channel within your overall DPDP compliance programme. Ensure that notices, purposes, and retention practices in your DPDP framework line up with how you configure ABDM consents and how partners access data through HIE-CM.
For smaller setups with few partners, HIS-based consent capture may be workable. As you scale across multiple labs, pharmacies, insurers, and digital channels, it becomes difficult to maintain a single source of truth, standard audit trails, and partner-level reporting using only an HIS or spreadsheets.
A dedicated consent management platform can centralise consent logic, expose APIs to your HIS/LIS/EMR and partner systems, and provide governance dashboards and reports. The build-versus-buy decision should weigh your engineering capacity, regulatory risk appetite, and the complexity of your partner ecosystem.
For clinical safety and business continuity, define fail-safe modes in advance. For example, you might allow time-limited “break glass” access for clinicians with enhanced logging, while pausing non-critical data sharing such as marketing campaigns until consent services are fully restored.
Your contracts and runbooks should specify how partners are notified, what temporary measures are acceptable, and how you will reconcile logs and consents after recovery. Test these scenarios through joint drills rather than assuming they will work in practice.
Health data is inherently sensitive, and emerging rules and guidance emphasise extra safeguards and careful handling for children’s personal data and other vulnerable groups. In practice, this often means stricter identity and relationship checks for parents or guardians, conservative data minimisation, shorter retention periods, and tighter restrictions on secondary use. Work closely with paediatrics, legal, and ethics teams to define and implement these higher standards.[5]
Sources
- Digital Personal Data Protection Act, 2023 - The Gazette of India, Government of India
- About ABDM - National Health Authority, Government of India
- Ayushman Bharat Digital Mission – Building Blocks and Architecture (v8.4 External Version) - National Health Authority / Ministry of Health and Family Welfare (hosted via Punjab Dental Council)
- Protecting healthcare privacy: Analysis of data protection developments in India - Indian Journal of Medical Ethics
- The Healthcare-Centric Guide to DPDP Rules 2025: What India’s Healthcare Providers & Companies Must Know - Elets eHealth
- Promotion page